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Most patients with COVID-19 receive antibiotics despite the fact that bacterial co-infections
are rare. This can lead to increased complications, including antibacterial resistance. We
aim to analyze risk factors for inappropriate antibiotic prescription in these patients and
describe possible complications arising from their use.
Methods
The SEMI-COVID-19 Registry is a multicenter, retrospective patient cohort. Patients with
antibiotic were divided into two groups according to appropriate or inappropriate
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prescription, depending on whether the patient fulfill any criteria for its use. Comparison was
made by means of multilevel logistic regression analysis. Possible complications of antibi-
otic use were also identified.
Results
Out of 13,932 patients, 3047 (21.6%) were prescribed no antibiotics, 6116 (43.9%) were
appropriately prescribed antibiotics, and 4769 (34.2%) were inappropriately prescribed anti-
biotics. The following were independent factors of inappropriate prescription: February-
March 2020 admission (OR 1.54, 95%CI 1.18–2.00), age (OR 0.98, 95%CI 0.97–0.99),
absence of comorbidity (OR 1.43, 95%CI 1.05–1.94), dry cough (OR 2.51, 95%CI 1.94–
3.26), fever (OR 1.33, 95%CI 1.13–1.56), dyspnea (OR 1.31, 95%CI 1.04–1.69), flu-like
symptoms (OR 2.70, 95%CI 1.75–4.17), and elevated C-reactive protein levels (OR 1.01 for
each mg/L increase, 95% CI 1.00–1.01). Adverse drug reactions were more frequent in
patients who received ANTIBIOTIC (4.9% vs 2.7%, p < .001).
Conclusion
The inappropriate use of antibiotics was very frequent in COVID-19 patients and entailed an
increased risk of adverse reactions. It is crucial to define criteria for their use in these
patients. Knowledge of the factors associated with inappropriate prescribing can be helpful.
Introduction
Since the beginning of 2020, the world has faced the threat posed by the coronavirus disease
2019 (COVID-19) pandemic. As of March 12th, more than 110 million people have been
infected and more than 2 million people have died worldwide [1].
During the first wave, it has been observed that most patients admitted with a COVID-19
had been prescribed antibiotics, including broad-spectrum antibiotics in a percentage of cases.
Antibiotic use has been described in more than 70% of cases [2, 3]. Suspicion of concomitant
bacterial pneumonia and evidence of superinfection may have been a motivating factor behind
this extensive use. However, some studies suggest that bacterial co-infection is rare, occurring
in less than 10% of cases [4, 5]. More recent literature have confirmed that bacterial co-infec-
tion and super-infection is rare, representing 8.5–12% of cases [3, 6]. Inappropriate antibiotic
prescribing in COVID-19 patients can lead to avoidable complications, including increased
bacterial resistance [7], Clostridioides difficile (CD) infection [8] reactions, renal impairment,
and more. All of the above negative repercussions are possible and yet no benefits to patients
have been described [9]. Therefore, several groups have sounded the alarm and requested the
intervention of antibiotic stewardship programs in these patients [10].
We aim to analyze systemic inappropriate antibiotic prescribing in patients with SARS--
CoV-2 infection in order to determine the proportion of patients who were inappropriately
prescribed antibiotics as well as to identify the factors associated with unjustified treatment.
This work also aims to describe the possible complications arising from antibiotic prescription.
The primary outcome was the proportion of inappropriate antibiotic and its risk factors com-
paring to appropriate antibiotic. Secondary outcomes included risk factor for inappropriate
prescription vs no antibiotic use, complications from antibiotic prescription and compare
inappropriate prescription during the study period.
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Patients and methods
The SEMI-COVID-19 Registry is an ongoing retrospective observational cohort study that
includes consecutive patients who were discharged after hospitalization or died due to
COVID-19 in 150 hospitals in Spain from March 1, 2020 on. This work analyzed data collected
up to June 23, 2020.
Study population and participants
The inclusion criteria for this study were: a) patients 18 years of age or older, b) confirmed
COVID-19 diagnosis, c) first hospital admission to a Spanish hospital participating in the registry,
d) discharge from the hospital or in-hospital death, and e) informationon antibiotic use during
hospitalization available. COVID-19 was confirmed by a positive real-time polymerase chain reac-
tion (PCR) test of a nasopharyngeal exudate sample, sputum, or bronchoalveolar wash or by a
positive result on a serological and a compatible clinical presentation. Patients could be included
in the registry with a first negative PCR if subsequent determination in the other samples was pos-
itive. The exclusion criteria were hospital readmissions of the same patient or absence of informed
consent. Patients were treated at the discretion of their attending physician.
Ethical consideration
Personal data were processed in compliance with Law 14/2007 of July 3, Biomedical Research,
as well as Regulation EU 2016/679 of the European Parlament and of the Council of 27 April
2016, General Data Protection Regulation and Organic Law 3/2018 of 5 December on the Pro-
tection of Personal Data and Guarantee of Digital Rights. The registry has the approval of the
Ethics and Research Committee of the Province of Malaga. The Department of Medicinal
Products for Human Use of the Spanish Medicines and Healthcare Products has classified the
study as "Non-Post-Authorization Observational Study". Patients were asked for a written
informed consent during hospital admission. Due to biosecurity reasons, the consent had not
witnessed. When it was not possible to obtain it for biosecurity reasons or because the patient
was already discharged, it was collected verbally, leaving evidence in their medical history.
Registry information and definitions
The methods of this registry have been fully described in previously published works [11]. In
summary, all consecutive patients who were discharged after March 1 on hospitals participat-
ing in the register were included. Data were collected anonymously and retrospectively by
local investigators in each center. The data collected include approximately 300 variables
grouped under several headings. Due to the characteristics of the database, it was not possible
to analyze the specific antibiotic prescribed within the different antibiotic families nor was it
possible to analyze the duration of treatment or the time it was started.
In order to classify antibiotic prescribing, the following criteria of appropriate prescribing
were considered: negative SARS-CoV-2 PCR (in a scenario of a patient admitted with pneu-
monia without confirmed COVID-19, the empirical use of antibiotics until COVID-19 confir-
mation could be justified), shock/sepsis, clinical symptoms, radiological findings or laboratory
test suggestive of bacterial superinfection, including purulent expectoration, unilateral alveolar
(with air bronchogram) infiltrate, significant pleural effusion, CT imaging that is not compati-
ble with COVID-19, and procalcitonin (PCT) equal to or greater than 0.5 ng/mL, and con-
firmed bacterial complications, including respiratory bacterial coinfection (at admission time)
or superinfection (later on admission) with microbial isolation, urinary tract infection, abdom-
inal infections, skin and soft tissue infection, and other infections. PCT elevation has been
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associated with bacterial superinfection in COVID-19 patients [12, 13], and some authors sug-
gest its use to guide antibiotic initiation in these patients [14]. Thus, prescribing was consid-
ered appropriate when patients who met any of these criteria received antibiotic treatment.
These criteria for the appropriate use of antibiotics are similar to those proposed in the litera-
ture by several authors [15–17]. During the first months of the pandemic, early evidence sug-
gested that macrolides could have inhibitory action on SARS-CoV-2 and immunomodulatory
effects on patients [18–20]. Accordingly, many local protocols in our country recommended
the use of macrolides in COVID-19 patients due to these effects, and not as an antibacterial
drug. We provide examples local protocols including this recommendation in S1 Annex.
Therefore, we decided to categorize patients who were prescribed macrolides without any
other antibiotic drug as patients with no antibiotic prescription, since we consider that, in
these patients, macrolides were not used for their antibiotic effect, but as an immunomodula-
tory and antiviral drug (comparable to lopinavir-ritonavir or hydroxychloroquine use).
Among the various entities included in the "other complications" variable in the registry (a
variable which was based on a free text), we manually identified the following complications
which could be potentially associated with antibiotic use: pharmacological hypertransaminase-
mia, drug-induced diarrhea, rash/allergy caused by antibiotics, CD diarrhea, invasive and
non-invasive candidiasis, QT prolongation, drug-induced neutropenia and drug-induced
thrombocytopenia. We defined flu-like symptoms as the presence of odynophagia, myalgia,
arthralgia, headache, or asthenia.
Study management
The promoter of this study is the Spanish Society of Internal Medicine (SEMI). The research-
ers who coordinated the study at each hospital agreed to participate in the study voluntarily
and without remuneration. The monitoring of the study is carried out by the SEMI scientific
committee and an independent agency.
Statistical analysis
Demographic, clinical, epidemiological, laboratory and diagnostic imaging data of the partici-
pating patients were analyzed. Quantitative variables were expressed as median (interquartile
range (IQR)). Categorical variables were expressed as absolute frequencies and percentages.
For univariant analysis, the chi-squared test was used for qualitative variables (or Fisher’s exact
test when necessary) and the Student’s t-test for quantitative variables (or Wilcoxon W when
necessary). Variables that achieved statistically significant and clinically relevant differences in
the univariant analysis were included in a single-step multivariate logistic regression analysis
model. Corrected odds ratio (OR) and 95% confidence intervals (CI) for inappropriate pre-
scription were provided for all the included variables. Bilateral p-values below 0.05 were con-
sidered significant. Statistical analysis was performed using the SPSS version 25 software
package (IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp).
Results
A total of 14,907 patients had been included in the registry as of June 23, 2020. All data neces-
sary for inclusion were available on 13,932 patients. Fig 1 shows the patient flowchart.
Antibiotics prescription
Of these 13,932 patients, systemic antibiotic other than macrolides were used in 10,885
(78.1%). The most commonly prescribed antibiotics were beta-lactams (72.2%), quinolones
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(13.4%), linezolid (2.2%), glycopeptides (1.6%), co-trimoxazole (0.6%), and tetracyclines
(0.6%). The rest of the antibiotics accounted for less than 0.3% of patients each.
Criteria for antibiotic prescription
Of all patients, 52.4% met at least one criterion for the use of antibiotics. The most common criteria
were unilateral alveolar infiltrate (17.5%), cough with purulent expectoration (15.5%), negative
SARS-CoV-2 PCR (11.9%), respiratory bacterial co-infection and/or superinfection (10.9%), sepsis
(6.2%), procalcitonin equal to or greater than 0.5 ng/mL (5.7%), significant pleural effusion (3.0%),
shock (4.5%), and positive pneumococcal and/or legionella urine antigens (1.5%). The presence of
superinfections other than respiratory superinfections was rare, including venous catheter-related
bacteremia (0.8%), urinary tract infection (0.8%), abdominal infection (0.3%), skin and soft tissue
infection (0.1%), other infections (0.1%). Table 1 summarizes the criteria for antibiotic prescription.
Inappropriate antibiotic prescription
In total, non-macrolide antibiotics were not prescribed in 3,047 patients (21.6%), whereas they
were appropriately prescribed in 6,116 patients (43.9%), and inappropriately prescribed in
Fig 1. Patient flowchart.
https://doi.org/10.1371/journal.pone.0251340.g001
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4,769 patients (34.2%). Accordingly, 43.8% of antibiotic prescriptions were considered inap-
propriate. The epidemiological, clinical, analytical, and radiological characteristics of patients
with appropriate vs inappropriate antibiotic prescribing and patients who were not prescribed
antibiotics vs patients with inappropriate prescribing are summarized in Tables 2 and 3,
respectively, as well as the risk factors, with adjusted OR for inappropriate prescribing.
Out of a total of 1078 critically ill patients who were admitted to ICU units, no antibiotics
were prescribed in 29 patients (2.7%), whereas they were appropriately prescribed in 833
patients (77.3%), and inappropriately prescribed in 216 patients (20.0%).
Antibiotic prescription over time
A total of 11,611 (83.3%) patients were admitted in February or March 2020 (group 1) whereas
2,321 patients (16.7%) were admitted later (group 2). In the first group, non-macrolides antibi-
otics were used in 9,231 patients (79.5%) compared to 1,654 (71.3%) in the second group admit-
ted after March, a statistically significant difference (p< .001). However, an indication for
antibiotics was less common in those admitted in the first group compared to the second group
(51.8% vs 55.1%, p = .003). Thus, inappropriate antibiotic use was less common in the second
group (28.0% vs 35.5%, p< .001). Fig 2 shows antibiotic prescription variation over time.
Potential adverse effects for antibiotic prescription
The occurrence of complications potentially resulting from pharmacologic prescription was
more frequent in patients with antibiotics (19.6% vs 10.5%, OR 2.07, 95% CI 1.82–2.35,
p<0.001). Due to the design of the register, it was not possible to know if acute renal injury
(AKI) was present at admission and, therefore, before antibiotic prescription. However, if we
exclude AKI from other complications, patients with antibiotics prescription were more likely
to have drug-related complication that patients without them (4.9% vs 2.7%, OR 1.84, 95% CI
1.45–2.32, p<0,001). The main complications potentially resulting from the use of antibiotics
are summarized in Table 4. The presence of complications was similar in patients with appro-
priate and inappropriate prescriptions.
Discussion
In this study, we aimed to analyze inappropriate antibiotic prescribing in patients with
COVID-19 as well as its risk factors. Inappropriate antibiotic prescribing was very high in our
Table 1. ATB prescription criteria in COVID-19 patients.
ATB prescription criteria Total (n = 13932) Appropriate ATB (n = 6116) No ATB (n = 3047)
Purulent expectoration 15.5% (2157) 29.8% (1816) 11.2% (341)
Sepsis 6.2% (853) 13.0% (789) 2.1% (64)
Shock 4.5% (625) 9.6% (587) 1.3% (38)
Unilateral alveolar infiltrate 17.5% (2411) 33.0% (2007) 13.7% (404)
Significant pleural effusion 3.0% (413) 5.7% (344) 2.3% (69)
CT no compatible with COVID-19 0.6% (88) 1.0% (63) 0.8% (25)
Negative first SARS-CoV2 PCR 12.1% (1660) 21.9% (1320) 11.3% (340)
PCT equal or greater than 0.5 ng/mL 5.7% (797) 11.6% (709) 2.9% (88)
Respiratory superinfection 10.9% (1508) 23.6% (1439) 2.3% (69)
Other superinfections 2.2% (314) 5.1% (311) 3 (0.1%)
Any criteria 52.4% (7294) 100% (6116) 38.7% (1178)
ATB: antibiotic. CT: Computed Tomography. PCT: Procalcitonin.
https://doi.org/10.1371/journal.pone.0251340.t001
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Table 2. Epidemiological, clinical and analytical characteristics according to the appropriate or inappropriate prescription of ATB.
Variable Univariant Multivariant Missing (10885)
Appropriate ATB (6116) Inappropriate ATB (4769) p OR (95% CI) p
Epidemiological
February-March admission (vs later) 83.6% (5113) 86.3% (4118) <0.001 1.27 (1.12–1.43) <0.001 0
Age 68.7 (57.7–77.2) 66.0 (56.5–77.2) <0.001 0.99 (0.98–1.00) <0.001 0
Sex (male) 60.3% (3689) 56.2% (2684) <0.001 0.87 (0.78–0.98) 0.031 0
Charlson Index 1 (0–2) 0 (0–1) <0.001 288
Age-Adjusted Charlson Index 3 (2–5) 2 (1–4) <0.001 0.87 (0.77–0.97) 0.018 288
Alcoholism 5.6% (333) 3.8% (172) <0.001 397
Smoking 27.7% (1610) 24.3% (1095) <0.001 561
Severe dependence 9.1% (550) 5.2% (244) <0.001 1.03 (0.64–1.66) 0.879 148
Arterial hypertension 53.8% (3286) 49.2% (2342) <0.001 0.99 (0.83–1.17) 0.899 17
Obesity 22.3% (1233) 22.9% (942) 0.643 1063
SOT 1.3% (80) 1.2% (59) 0.148 114
IS 4.0% (244) 3.2% (151) 0.468 37
Coronary disease 6.6% (403) 5.5% (262) 0.017 17
Heart failure 9.0% (547) 5.4% (257) <0.001 0.94 (0.69–1.26) 0.684 23
COPD 8.6% (527) 5.6% (267) <0.001 1.04(0.77–1.39) 0.799 22
Asthma 7.7% (470) 6.3% (298) 0.004 24
Stroke 3.2% (196) 2.3% (109) 0.004 22
Cognitive impairment 12.1% (736) 8.4% (402) <0.001 0.98 (0.72–1.33) 0.901 20
Chronic kidney failure 7.7% (474) 4.3% (204) <0.001 0.77 (0.54–1.08) 0.135 29
Active cancer 6.8% (415) 5.5% (261) 0.005 18
Diabetes mellitus 14.7% (895) 14.2% (678) 0.519 25
AID 2.4% (145) 2.2% (107) 0.660 31
AIDS 0.3% (20) 0.2% (8) 0.149 43
Non-AIDS HIV 0.8% (46) 0.6% (27) 0.235 43
At least one comorbidity 82.3% (5035) 76.7% (3657) <0.001 0.81 (0.68–0.97) 0.022 0�
Clinical symptoms
Dry cough 46.6% (2838) 72.0% (3424) <0.001 3.59 (3.13–4.13) <0.001 41
Arthromyalgia 28.3% (1711) 32.9% (1543) <0.001 0.91 (0.78–1.06) 0.238 154
Ageusia 6.3% (375) 8.0% (370) 0.001 352
Anosmia 5.5% (323) 7.3% (338) <0.001 355
Asthenia 43.1% (2589) 45.5% (2130) 0.014 192
Odynophagia 9.0% (539) 10.1% (473) 0.047 222
Headache 10.0% (598) 12.1% (567) 0.001 206
Fever 64.7% (3945) 67.0% (3184) 0.014 1.11 (1.01–1.23) 0.031 40
Dyspnea 61.1% (3719) 57.0% (2706) <0.001 0.99 (0.70–1.40) 0.984 49
Diarrhea 20.9% (1268) 25.9% (1220) <0.001 1.15 (0.79–1.67) 0.457 101
Abdominal pain 6.0% (363) 6.6% (308) 0.255 150
Crackles 54.6% (3243) 53.7% (2492) 0.387 307
Flu-like symptoms 4800 (78.5%) 4549 (95.4%) <0.001 3.2 (1.67–6.13) <0.001 0�
Laboratory and image test
pH 7.45 (7.42–7.49) 7.45 (7.42–7.48) 0.316 2370
pO2 (%) 66 (55–76) 65 (57–75) 0.251 2886
PaFi 281 (235–332) 294 (249–333) <0.001 1,00 (1,00–1,04) 0,110 2990
Hemoglobin (g/dL) 13.6 (12.3–14.7) 14.1 (12.8–14.9) <0.001 1.06 (0.97–1.16) 0.140 118
Plateles (x109/L) 199 (154–256) 195 (149–268) 0.953 118
(Continued)
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patients. Younger age; less comorbidity; and the presence of dry cough, flu-like symptoms,
fever, bilateral interstitial infiltrates, and increased C-Reactive Protein (CRP) levels were inde-
pendently associated with inappropriate prescribing.
The use of antibiotics in our patients was common, and accounts for more than three quar-
ters of patients. This percentage is similar to what has been found in other cohorts [21–23] and
meta-analyses [3, 4, 6]. The percentage of antibiotic use was especially high in ICU patients,
although the inappropriate use in this setting was relatively low (20.0%) The ample use of anti-
biotics contrasts with the low incidence of bacterial co-infection or superinfection found. Only
10% of patients had confirmed pulmonary superinfection while 2% had superinfection of
another origin, the most common being venous catheter-related bacteremia and urinary tract
infection. Again, these data are in line with those described previously by other authors [4, 22,
24], with higher percentages described in critical patients [25, 26], which could justify the
higher use of antibiotic use that we found in those patients. It should be noted that, due to the
design of our database, we were unable to distinguish between community-acquired pulmo-
nary co-infection and nosocomial superinfection, though the latter [21, 22, 25, 27].
One half of our patients met one or more appropriate antibiotic use criteria. The criteria
selected for its use in patients with SARS-CoV-2 infection in this work are similar to those pro-
posed by other authors in several publications [10, 16, 28, 29]. With this in mind, antibiotics
were used inappropriately in more than a third of all patients. Independent risk factors for
inappropriate prescribing were younger age; less comorbidity; and the presence of dry cough,
fever, flu-like symptoms, and bilateral interstitial infiltrates. Independent risk factors for inap-
propriate prescribing vs no antibiotic prescribing were younger age; presence of dry cough,
fever, dyspnea, flu-like symptoms, or higher CRP levels. In both cases, the factors that were
most strongly linked to inappropriate prescribing were dry cough or flu-like symptoms. We
also detected a lower percentage of inappropriate antibiotic prescribing in patients who were
admitted to the hospital after March 2020, which can perhaps be explained by healthcare pro-
fessionals’ greater knowledge of the disease.
The use of antibiotics in these patients is not without risk. In our series, we found more
adverse drug reactions in patients receiving antibiotics. AKI, pharmacological
Table 2. (Continued)
Variable Univariant Multivariant Missing (10885)
Appropriate ATB (6116) Inappropriate ATB (4769) p OR (95% CI) p
Leucocytes (x109/L) 6.4 (5.0–8.6) 6.5 (5.1–8.6) <0.001 1.00 (1.00–1.00) 0.912 118
Lymphocytes (x109/L) 0.8 (0.6–1.1) 0.9 (0,6–1.2) 0.191 118
Neutrophils (x109/L) 3.2 (2.4–4.9) 3.7 (2.6–4.8) <0.001 118
CRP (mg/L) 71 (15–146) 50 (12–115) <0.001 0.99 (0.98–1.01) 0.220 768
LDH (U/L) 346 (245–512) 341 (261–444) <0.001 1044
Ferritin (microg/L) 662 (324–1121) 672 (359–1507) 0.363 3019
IL-6 (ng/L) 32.8 (12.5–74.0) 24.0 (6.5–66.0) 0.008 1.00 (0.99–1.01) 0.500 5335
D-Dimer (ng/mL) 0.77 (0.43–1.38) 0.59 (0.36–1.06) <0.001 1.00 (1.00–1.00) 0.361 1128
Interstitial infiltrate 58.1% (3530) 71.4% (3333) <0.001 1.40 (1.30–1.54) <0.001 78
Quantitative variables are expressed as median (interquartile range). Qualitative variables as percentage (total number). Variables that achieved statistically significant
and with a clinically relevant difference between groups were included in a single-step multivariate logistic regression model. Adjusted OR for inappropriate
prescription are provided for all variables included in the model. ATB: antibiotic. OD: Odds Ratio. CI: Confidence Interval. SOT: Solid Organ Transplant. IS:
immunosuppression. COPD: Chronic Obstructive Pulmonary Disease. AID: Autoimmune Disease. AIDS: Acquired Human Immunodeficiency Syndrome. HIV:
Human Immunodeficiency Virus. IL-6: Interleukin 6
https://doi.org/10.1371/journal.pone.0251340.t002
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Table 3. Epidemiological, clinical and analytical characteristics according to non-prescription or inappropriate prescribing of ATB.
Variable Univariant Multivariant Missing (n = 7816)
No ATB (3047) Inappropriate ATB (4769) p OR (95% CI) p
Epidemiological
February-March admission (vs later) 78.1% (2380) 86.3% (4118) <0.001 1.54 (1.18–2.00) 0.002 0
Age 66.1 (53.0–77,5) 66.0 (56.5–77.2) <0.001 0.98 (0.97–0.99) 0.014 0
Sex (male) 52.0% (1583) 56.2% (2677) <0.001 0.91 (0.71–1.16) 0.455 9
Charlson Index 1 (0–2) 0 (0–1) 0.339 197
Age-Adjusted Charlson Index 3 (1–5) 2 (1–4) 0.011 0.99 (0.91–1.06) 0.807 197
Alcoholism 4.1% (123) 3.8% (172) 0.401 269
Smoking 20.7% (607) 24.3% (1095) <0.001 376
Severe dependence 6.5% (193) 5.2% (244) 0.053 132
Arterial hypertension 56.3% (3286) 49.2% (2342) 0.015 0.91 (0.68–1.21) 0.536 11
Obesity 18.1% (1233) 21.9% (942) <0.001 686
SOT 1.1% (33) 1.2% (59) 0.454 112
IS 3.1% (94) 3.2% (151) 0.902 26
Coronary disease 5.3% (161) 5.5% (262) 0.694 10
Heart failure 6.1% (187) 5.4% (257) 0.162 14
COPD 5.4% (163) 5.6% (267) 0.644 11
Asthma 8.1% (245) 6.3% (298) 0.003 17
Stroke 2.8% (84) 2.3% (109) 0.192 10
Cognitive impairment 8.6% (261) 8.4% (402) 0.814 22
Chronic kidney failure 5.2% (157) 4.3% (204) 0.082 11
Active cancer 6.0% (184) 5.5% (261) 0.292 7
Diabetes mellitus 12.0% (366) 14.2% (678) 0.006 16
AID 2.3% (70) 2.2% (107) 0.875 22
AIDS 0.4% (12) 0.2% (8) 0.083 27
Non-AIDS HIV 0.8% (24) 0.6% (27) 0.232 27
At least one comorbidity 75.1% (2289) 76.7% (3657) 0.015 1.43 (1,05–1.94) 0.025 0
Clinical symptoms
Dry cough 59.7% (1815) 72.0% (3424) <0.001 2.51 (1.94–3.26) <0.001 25
Arthromyalgia 28.9% (874) 32.9% (1543) <0.001 102
Ageusia 8.9% (266) 8.0% (370) 0.188 211
Anosmia 8.0% (238) 7.3% (338) 0.316 216
Asthenia 40.6% (1226) 45.5% (2130) <0.001 110
Odynophagia 10.0% (301) 10.1% (473) 0.814 125
Headache 12.7% (384) 12.1% (567) 0.442 122
Fever 55.5% (1688) 67.0% (3184) <0.001 1.33 (1.13–1.56) 0.001 25
Dyspnea 51.6% (1566) 57.0% (2706) <0.001 1.31 (1.04–1.69) 0.044 34
Diarrhea 23.9% (722) 25.9% (1220) 0.048 64
Abdominal pain 6.9% (209) 6.6% (308) 0.522 97
Crackles 46.8% (1388) 53.7% (2492) <0.001 0.89 (0.70–1.13) 0.358 216
Flu-like symptoms 90.2% (2747) 95.4% (4549) <0.001 2.70 (1.75–4.17) <0.001 0
Laboratory and image test
pH 7.44 (7.41–7.47) 7.45 (7.42–7.48) <0.001 1952
pO2 (%) 68 (59–81) 65 (57–75) <0.001 0.99 (0.98–1.01) 0.544 2370
PaFi 304 (253–361) 294 (249–333) <0.001 2450
Hemoglobin (g/dL) 13,9 (12.7–15.0) 14,1 (12.8–14.9) 0.009 156
Platelets (x109/L) 194 (153–249) 195 (149–268) 0.050 156
(Continued)
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hypertransaminasemia, drug-induced diarrhea, and candidiasis were more common in
patients who received them. In addition, we identified an incidence of 2.5 allergic reactions
per 1000 prescriptions, a similar figure to what has been reported in the recent literature [30].
We also identified an incidence of 2.7 cases CD infection per 1000 prescriptions, a higher inci-
dence than what has been found in COVID-19 patients by other authors [31]. One of the most
feared secondary effect of inappropriate antibiotic use is an increase in microbial resistance [2,
Table 3. (Continued)
Variable Univariant Multivariant Missing (n = 7816)
No ATB (3047) Inappropriate ATB (4769) p OR (95% CI) p
Leucocytes (x109/L) 6.1 (4.7–8.1) 6.5 (5.1–8.6) 0.183 156
Lymphocytes (x109/L) 1.0 (0.7–1.4) 0.9 (0.6–1.2) <0.001 1.00 (1.00–1.00) 0.750 156
Neutrophils (x109/L) 4.3 (3.0–6.2) 3.7 (2.6–4.8) 0.007 156
CRP (mg/L) 32.7 (8.7–88.0) 50 (12–115) <0.001 1.01 (1,00–1.01) 0.001 1776
LDH (U/L) 296 (230–401) 341 (261–444) <0.001 1.00 (0.99–1.00) 0.560 1776
Ferritin (microg/L) 487 (222–1090) 672 (359–1507) <0.001 1.00 (1.00–1.00) 0.581 1776
IL-6 (ng/L) 27.5 (10.7–54.3) 24.0 (6.5–66.0) 0.272 6810
D-Dimer (ng/mL) 0.61 (0.36–1.12) 0.59 (0.36–1.06) 0.114 1709
Interstitial infiltrate 58.9% (1741) 71.4% (3333) <0.001 1.02 (0.88–1.23) 0.821 127
Quantitative variables are expressed as median (interquartile range). Qualitative variables as percentage (total number). Variables that achieved statistically significant
and with a clinically relevant difference between groups were included in a single-step multivariate logistic regression model. Adjusted OR for inappropriate
prescription are provided for all variables included in the model. ATB: antibiotic. OD: Odds Ratio. CI: Confidence Interval. SOT: Solid Organ Transplant. IS:
immunosuppression. COPD: Chronic Obstructive Pulmonary Disease. AID: Autoimmune Disease. AIDS: Acquired Human Immunodeficiency Syndrome. HIV:
Human Immunodeficiency Virus. IL-6: Interleukin 6
https://doi.org/10.1371/journal.pone.0251340.t003
Fig 2. Antibiotic prescription variation over time. Abscissa axis corresponds to admission date. Ordinate axis corresponds to
the percentage of patients with antibiotic prescription (scheme 0.9 equals to 90%). Data are shown for the period with more than
20 admissions per day.
https://doi.org/10.1371/journal.pone.0251340.g002
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7, 32]. It is well known that the spread of multidrug-resistant bacteria is closely related to anti-
biotic exposure [2, 32, 33]. Although due to limitations in the database we could not analyze
antibiotic resistance, we can speculate that the overuse of antibiotic and inappropriately pre-
scribed antibiotics in COVID-19 patients can induce an increase in antibiotic resistance,
which have already been noted by some authors [34].
Therefore, by inappropriately prescribing antibiotics, we are exposing patients with SARS--
CoV-2 infection to pharmacological toxicity and increased risk of morbidity despite the fact
that no benefits have been proven, even in critical patients [35]. Inappropriate antibiotic pre-
scribing may be due to multiple factors, such as an overload of the healthcare system, confu-
sion with bacterial pneumonia, etc. Moreover, several local management protocols in March
and April 2020 advised physicians to prescribed empirical antibiotics (such as cephalosporins)
to nearly all patients regardless of whether there was an indication. Those protocols must be
changed and the recommendation to prescribe empirical antibiotics in absence of a possible of
bacterial superinfection must be removed.
The need to implement specific criteria for antibiotic use in COVID-19 patients has previ-
ously been emphasized [36] and indeed, clinical guidelines for its prescription in COVID-19
patients [37]. In this document, the main recommendation is to restrict the use of these drugs,
especially at the time of admission, when bacterial infections are less common [22]. It even rec-
ommends early suspension of the antibiotic courses that may have been started in the emer-
gency department. It may be challenging to discern which patients warrant antibiotic
prescription and in which patients antibiotic use may be inappropriate. It is possible that our
work could help identify patients who have been inappropriately prescribed. Accordingly,
young patients and those without comorbidity who are prescribed antibiotics for dry cough,
fever, flu-like symptoms, interstitial infiltrates, or increased CRP may be receiving them inap-
propriately and, in the absence of other data indicating their use, suspension of treatment
could be considered. Another possible action should be to improve formation regarding
appropriate antibiotic therapy and antimicrobial therapy and stewardship principles, both in
general setting and specifically in COVID-19 patients, as has been shown previously by other
authors that those aspects are poorly addressed in medical training programs [38].
Our work is based on a large, multicenter cohort and has the strengths inherent to these
types of works: appropriate representation of different regions, which reduces biases of local
Table 4. Comparison of incidence of complications potentially associated with ATB.
Complication Without ATB (n = 3047) With ATB (n = 10885) P Appropriate ATB (n = 4769) Inappropriate ATB (n = 6116) p
Hypertransaminasemia 1.0% (29) 2.1% (226) <0.001 2.1% (129) 2.0% (97) 0.787
Iatrogenic diarrhea 0.8% (25) 1.3% (137) 0.025 1.0% (62) 1.6% (75) 0.012
AKI 8.1% (246) 15.6% (1690) <0.001 19.9% (1211) 10.1% (479) <0.001
Allergic reaction to ATB 0.1% (3) � 0.2% (25) 0.072 0.2% (12) 0.3% (13) 0.426
Prolongated QT 0.5% (14) 0.3% (37) 0.334 0.4% (22) 0.4% (15) 0.688
Neutropenia 0.2% (5) 0.2% (18) 0.988 0.2% (13) 0.1% (5) 0.235
Thrombocytopenia 0.2% (5) 0.3% (38) 0.068 0.4% (26) 0.3% (12) 0.142
Clostridioides difficile <0.1% (2) � 0.3% (28) 0.026 0.3% (18) 0.2% (10) 0.449
Candidemia <0.1% (2) 0.1% (14) 0.181 0.2% (14) 0 0.002
Candidiasis <0.1% (2) 0.4% (39) 0.003 0.4% (23) 0.3% (16) 0.750
Any AR (excluding AKI) 2.7% (83) 4.9% (533) <0.001 4.9% (300) 4.9% (233) 0.964
Any AR (including AKI) 10.5% (321) 19.6% (2134) <0.001 23.7% (1448) 14.4% (686) <0.001
ATB: Antibiotics. AKI: Acute Kidney Injury, AR: adverse reaction.
�Effects that were attached to macrolide.
https://doi.org/10.1371/journal.pone.0251340.t004
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origin and increases external validity, as well as a large sample size, which provides statistical
power. However, the study also has limitations. First, the main limitation is that although the
database contains data on more than 300 variables, it was not specifically designed to analyze
inappropriate antibiotic prescribing. Therefore, some important variables for determining
whether or not the prescription was appropriate (such as antimicrobial spectrum, start time,
duration of the course, etc.) were not available. We were not able to separately analyze antibi-
otic courses that began at the time of hospital admission versus those initiated later. Second,
the data were collected by a large number of researchers from different centers, which could
have led to heterogeneity in data collection, especially in the "other complications" variable
and in the identification of bacterial complications. Third, our study is observational in nature,
which prevents us from determining causal relationships. Fourth, our criteria of appropriate
antibiotic prescribing are based in scarce low-quality evidence and it may be inadequate. How-
ever, our criteria were carefully selected based on the most recent literature evidence available.
Although our selected criteria for appropriate antibiotic use may be too inclusive, until there is
published more evidence on antibiotic use in COVID-19 patients (which is urgently needed),
they should be considered as valid. Finally, due to limits in the allowed analysis of the database,
we could not assess the association between antibiotic prescription and outcome, including
mortality or readmissions. However, previous data shows that there is little or no benefic in
their use without evidence of bacterial infection [21].
In conclusion, inappropriate use of antibiotics in our patients was a common phenomenon.
Lower age, less comorbidity, the presence of dry cough, flu-like symptoms, fever, bilateral
interstitial infiltrates and increased CRP were independently associated with inappropriate
prescription. Less inappropriate prescription were detected in patients admitted after March.
Widespread antibiotic prescribing carries an increased risk of adverse reaction and probably
other unwanted effects (such as possible increased bacterial resistances), without benefit. It is
therefore essential to integrate antibiotic use optimization programs in patients with SARS--
CoV2 infection. More research is needed to identify patients which warrant antibiotic
prescription.
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